The Company anticipates filing its NDA for GTx-104 in the second quarter of 2025. Acceptance of the NDA will be subject to the FDA’s review of the complete filing.

The injectable formulation of nimodipine is in clinical stages, being developed for IV infusions in patients with aneurysmal subarachnoid haemorrhage (aSAH), a type of stroke caused by the rupture ...

In hypertensive patients, IV medications such as nicardipine can ... the level is stable and until supplementation is weaned. Nimodipine is initiated on admission in all patients with SAH for ...